Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 compared to placebo over 14 days twice a day dosing in multiple ascending doses in subjects with stable schizophrenia.
This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Psychiatrically stable (≥3 months) male and female subjects with schizophrenia of non-childbearing potential between the ages of 18 and 55 years, inclusive.
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>55 kg (121 lbs).
DSM-IV Diagnosis of Schizophrenia; on stable medication treatment regimen ≥2 months.
You may not be if
Suicide attempt within 3 months prior to screening.
History of or risk of seizures; head injury with long term abnormal resulting condition, abnormal EEG, clinically significant additional diseases or conditions, current medication with a significant risk of seizures, currently receiving antipsychotic medications.
